Advances in pathogenesis and treatment of ANCA-associated vasculitis

Discovery Medicine

Volumn 18, Issue 99, 2014, Pages 195-201

  Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; MYELOBLASTIN; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CELL INFILTRATION; CELLULAR IMMUNITY; DISEASE COURSE; EOSINOPHIL; GLOMERULONEPHRITIS; GRANULOMATOUS INFLAMMATION; HUMAN; LEUKOCYTE ACTIVATION; META ANALYSIS (TOPIC); MICROSCOPIC POLYANGIITIS; NONHUMAN; PATHOGENESIS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SMALL VESSEL VASCULITIS; SPLEEN CELL; STAPHYLOCOCCUS AUREUS; WEGENER GRANULOMATOSIS; ANIMAL; BLOOD; GRANULOMATOSIS WITH POLYANGIITIS; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOMARKERS; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNITY, CELLULAR; MYELOBLASTIN;

EID: 84920869274     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CGM. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 70(5):938-947, 2006.
2. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CGM. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 58(7):2196-2205, 2008.
3. Abdulahad WH, Kallenberg CGM, Limburg PC, Stegeman CA. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60(9):2830-2838, 2009.
4. Abdulahad WH, Lepse N, Stegeman CA, Huitema MG, Doornbos-van der Meer B, Tadema H, Rutgers A, Limburg PC, Kallenberg CG, Heeringa P. Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA). Arthritis Res Ther 15(3):R70, 2013.
5. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 93(4):398-401, 2004.
6. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CGM, Limburg PC, Tervaert JW. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43(9):2025-2033, 2000.
7. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fervenza FC, Specks U. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 64(11):3770-3778, 2012.
8. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 87(11):4115-4119, 1990.
9. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Decaux O, Desmurs-Clavel H, Gobert P, Quemeneur T, Blanchard-Delaunay C, Godmer P, Puechal X, Carron PL, Hatron PY, Limal N, Hamidou M, Bonnotte B, Ravaud P, Mouthon L; for the FVSG. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis: a prospective study in 117 patients. Presse Med 42(4P2):679, 2013.
10. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116(6):488-498, 1992.
11. Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 167(1):47-58, 2005.
12. Huugen D, van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 71(7):646-654, 2007.
13. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg GCM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, et al. 2012 Revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65(1):1-11, 2013.
14. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211-220, 2010.
15. Kallenberg CGM. Churg-Strauss syndrome: just one disease entity? Arthritis Rheum 52(9):2589-2593, 2005.
16. Kallenberg CGM. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody -associated vasculitis? Curr Opin Rheum 26(3):292-298, 2014.
17. Kallenberg CGM. Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol 10(8):484-493, 2014.
18. Kettritz R. How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. Clin Exp Immunol 169(3):220-228, 2012.
19. Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, Ytterberg SR, Hoffman GS, Krischer JP, Merkel PA; Vasculitis Clinical Research Consortium. An open-label trial of abatacept (CTLA4-Ig) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 73(7):1376-1379, 2014.
20. Lepse N, Abdulahad WH, Kallenberg CGM, Heeringa P. Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev 11(2):77-83, 2011.
21. Little MA, Al-Ani B, Ren S, Al Nuaimi H, Leite M Jr, Alpers CE, Savage CO, Duffield JS. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One 7(1):e28626, 2012.
22. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hruskova Z, Little MA, Martorana D, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367(3):214-223, 2012.
23. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross WL, Hauser T, Hellmich B, Jayne DR, Kallenberg CGM, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman CA, Eatts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310-317, 2009.
24. Radford DJ, Luu NT, Hewins P, Nash GB, Savage C. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 44(12):2851-2861, 2001.
25. Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, McGregor J, Burkart M, Hogan SL, Hu Y, Winnik W, Nachman PH, Stegeman CA, Niles J, Heeringa P, Kitching AR, HoldsworthS, Jennette JC, Preston GA, Falk RJ. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 123(4):1773-1783, 2013.
26. Savage CO, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 141(2):335-342, 1992.
27. Schönermarck U, Grosss WL, de Groot K. Treatment of ANCA-associated vasculitis. Nat Rev Nephrol 10(1):25-36, 2013.
28. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369(5):417-427, 2013.
29. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120(1):12-17, 1994.
30. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CGM. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 335(1):16-20, 1996.
31. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221-232, 2010.
32. Tadema H, Abdulahad WH, Lepse N, Stegeman CA, Kallenberg CGM, Heeringa P. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology 50(4):689-696, 2011.
33. van Timmeren MM, Heeringa P. Pathogenesis of ANCA-associated vasculitis: recent insights from animal models. Curr Opin Rheumatol 24(1):8-14, 2012.
34. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - a meta-analysis. Rheumatology 51(1):100-109, 2012.
35. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, van der Giessen M, van der Hem GK, The TH. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1(8426):425-429, 1985.
36. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110(7):955-963, 2002.
37. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170(1):52-64, 2007.
38. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC. C5a receptor (CD88) blockade protects against MPO-ANCA glomerulonephritis. J Am Soc Nephrol 25(2):225-231, 2014.